Illumina, Inc.
(NASDAQ : ILMN)

( )
ILMN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 0.83%745.682.6%$767.75m
AMGNAmgen, Inc. 0.34%233.821.4%$621.98m
MRNAModerna, Inc. -0.04%125.620.0%$612.25m
BIIBBiogen, Inc. -2.15%261.691.8%$573.08m
GILDGilead Sciences, Inc. 0.21%65.451.0%$559.47m
VRTXVertex Pharmaceuticals, Inc. 0.46%302.021.9%$432.92m
ILMNIllumina, Inc. 6.56%218.523.2%$428.55m
SNSSSunesis Pharmaceuticals, Inc. -1.21%4.080.7%$285.21m
SAVACassava Sciences, Inc. -1.80%40.970.0%$181.06m
BNTXBioNTech SE -0.28%137.190.0%$112.04m
TECHBio-Techne Corp. 0.00%308.554.5%$100.54m
BMRNBioMarin Pharmaceutical, Inc. 1.84%89.534.2%$90.99m
NVAXNovavax, Inc. -3.61%18.7075.6%$84.10m
PRTAProthena Corp. Plc 1.15%58.1113.8%$78.29m
CRSPCRISPR Therapeutics AG -1.58%64.630.6%$77.63m

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.